ANM Adaptive Neuromodulation GmbH
Milestones in ANM's still-young corporate history include the European registration from February 2010 in conjunction with the CE mark and TÜV certification, followed by the market launch of the Acoustic T30 CR® neurostimulator for the treatment of chronic tinnitus. Then in December 2011 the American health authority FDA (Food and Drug Administration) granted approval for Acoustic CR® Neuromodulation with the ANM T30 CR® Tinnitus Therapy System in the USA.
Future scientific highlights:
Since November 2011: Start of a 12-months Real Life Tinnitus Study with 200 patients in 20 German study centres.
Q1 2012: Start of a multicentre, randomized, double-blinded, placebo-controlled clinical long-term tinnitus study enrolling approx. 100 patients in Great Britain.
“Federal (USA) law restricts this device to sale by or on the order of a physician, audiologist or other hearing healthcare professional.”
“CAUTION: The information presented on this homepage may show features and devices/components that are not available in some international markets. Labeling may vary in details for particular markets. Clients should contact ANM GmbH their local dealer to receive information on availability and specification of products in their country.”
Last Updated ( Wednesday, 02 April 2014 10:19 )